Gene therapy progress spurs competition in biotech buyouts

Drugmakers looking to buy their way into gene therapy are finding healthy competition for promising biotechs, regulatory filings from recent takeovers show, underscoring the renewed momentum behind a field seeking one-time treatments for genetic diseases.